ATE553778T1 - Für humanes hepcidin spezifische antikörper - Google Patents

Für humanes hepcidin spezifische antikörper

Info

Publication number
ATE553778T1
ATE553778T1 AT08835406T AT08835406T ATE553778T1 AT E553778 T1 ATE553778 T1 AT E553778T1 AT 08835406 T AT08835406 T AT 08835406T AT 08835406 T AT08835406 T AT 08835406T AT E553778 T1 ATE553778 T1 AT E553778T1
Authority
AT
Austria
Prior art keywords
antibodies specific
human hepcidin
hepcidin
human
antigen
Prior art date
Application number
AT08835406T
Other languages
English (en)
Inventor
Sophie Vaulont
Hugues Gascan
Josy Froger
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE553778T1 publication Critical patent/ATE553778T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT08835406T 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper ATE553778T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291196 2007-10-02
PCT/IB2008/003310 WO2009044284A1 (en) 2007-10-02 2008-10-02 Antibodies specific for human hepcidin

Publications (1)

Publication Number Publication Date
ATE553778T1 true ATE553778T1 (de) 2012-05-15

Family

ID=38983917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08835406T ATE553778T1 (de) 2007-10-02 2008-10-02 Für humanes hepcidin spezifische antikörper

Country Status (8)

Country Link
US (1) US8487081B2 (de)
EP (1) EP2200647B1 (de)
JP (1) JP2010539969A (de)
CN (1) CN101903044A (de)
AT (1) ATE553778T1 (de)
CA (1) CA2701694A1 (de)
ES (1) ES2385772T3 (de)
WO (1) WO2009044284A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) * 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
BR112012003701A2 (pt) 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2968503B1 (de) * 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin-antikörper und verwendungen davon
WO2016049036A1 (en) * 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JPWO2022154121A1 (de) * 2021-01-18 2022-07-21

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2448382C (en) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
AR065083A1 (es) 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana

Also Published As

Publication number Publication date
US8487081B2 (en) 2013-07-16
EP2200647A1 (de) 2010-06-30
CA2701694A1 (en) 2009-04-09
WO2009044284A1 (en) 2009-04-09
US20100285027A1 (en) 2010-11-11
JP2010539969A (ja) 2010-12-24
EP2200647B1 (de) 2012-04-18
ES2385772T3 (es) 2012-07-31
CN101903044A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CU24058B1 (es) Antagonistas de pcsk9
EA201370081A1 (ru) Антитела к cd48 и их применение
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
ECSP10010270A (es) Anticuerpos bivalentes biespecíficos
JO3097B1 (ar) الأجسام المضادة c-Met
BR112012007365A2 (pt) proteínas de ligação à il-1
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
EA201790757A1 (ru) Связывающие антиген cd27l белки
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
MY177564A (en) Anti-nr10 antibody and use thereof
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
CR20110400A (es) Proteinas de enlace al receptor cgrp humano